1228 Stock Overview
A biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
CANbridge Pharmaceuticals Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | HK$0.30 |
52 Week High | HK$1.70 |
52 Week Low | HK$0.25 |
Beta | -0.78 |
11 Month Change | -4.69% |
3 Month Change | -28.24% |
1 Year Change | -82.77% |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -96.57% |
Recent News & Updates
Shareholder Returns
1228 | HK Biotechs | HK Market | |
---|---|---|---|
7D | -4.7% | 2.4% | -0.02% |
1Y | -82.8% | -32.2% | -5.2% |
Return vs Industry: 1228 underperformed the Hong Kong Biotechs industry which returned -32.2% over the past year.
Return vs Market: 1228 underperformed the Hong Kong Market which returned -5.2% over the past year.
Price Volatility
1228 volatility | |
---|---|
1228 Average Weekly Movement | 12.2% |
Biotechs Industry Average Movement | 7.8% |
Market Average Movement | 6.5% |
10% most volatile stocks in HK Market | 13.8% |
10% least volatile stocks in HK Market | 3.6% |
Stable Share Price: 1228's share price has been volatile over the past 3 months.
Volatility Over Time: 1228's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2012 | 100 | James Qun Xue | www.canbridgepharma.com |
CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide. The company offers Hunterase, an enzyme replacement therapy for the treatment of Hunter syndrome; NERLYNX (Neratinlib), a potent irreversible tyrosine kinase inhibitor for HER2-positive breast cancer; and Livmarli, an oral, minimally-absorbed, reversible IBAT inhibitor for the treatment of alagille syndrome and progressive familial intrahepatic cholestasis. It also engages in the development of CAN008, a CD95-Fc fusion protein that is in Phase 2/3 clinical trial for the treatment of glioblastoma multiforme; CAN106, an anti-C5 mAb that has completed Phase I clinical trial for paroxysmal nocturnal hemoglobinuria; and CAN103, a recombinant human enzyme replacement therapy (ERT) that is in Phase 2/3 clinical trials for gaucher disease.
CANbridge Pharmaceuticals Inc. Fundamentals Summary
1228 fundamental statistics | |
---|---|
Market cap | HK$129.58m |
Earnings (TTM) | -HK$413.51m |
Revenue (TTM) | HK$112.29m |
1.2x
P/S Ratio-0.3x
P/E RatioIs 1228 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
1228 income statement (TTM) | |
---|---|
Revenue | CN¥102.87m |
Cost of Revenue | CN¥38.71m |
Gross Profit | CN¥64.16m |
Other Expenses | CN¥443.00m |
Earnings | -CN¥378.84m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.89 |
Gross Margin | 62.37% |
Net Profit Margin | -368.26% |
Debt/Equity Ratio | -76.2% |
How did 1228 perform over the long term?
See historical performance and comparison